KDR and neoplasm: We also show that the interference of VEGF receptor inhibitors with anti-tumor innate immunity can be circumvented by using sorafenib, a multi-RTKI with greatly reduced VEGFR2 inhibitory activity compared to VEGF receptor-targeted anti-angiogenic drugs, which largely spares VEGFR from inhibition (Table 1) [32,34].